These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 8406340)

  • 1. Growth hormone (GH) response to combined pyridostigmine and GH-releasing hormone administration in patients with Prader-Labhard-Willi syndrome.
    Cappa M; Grossi A; Borrelli P; Ghigo E; Bellone J; Benedetti S; Carta D; Loche S
    Horm Res; 1993; 39(1-2):51-5. PubMed ID: 8406340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced growth hormone (GH) responsiveness to combined GH-releasing hormone and pyridostigmine administration in the Prader-Willi syndrome.
    Grugni G; Guzzaloni G; Moro D; Bettio D; De Medici C; Morabito F
    Clin Endocrinol (Oxf); 1998 Jun; 48(6):769-75. PubMed ID: 9713567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new test for the diagnosis of growth hormone deficiency due to primary pituitary impairment: combined administration of pyridostigmine and growth hormone-releasing hormone.
    Ghigo E; Imperiale E; Boffano GM; Mazza E; Bellone J; Arvat E; Procopio M; Goffi S; Barreca A; Chiabotto P
    J Endocrinol Invest; 1990 Apr; 13(4):307-16. PubMed ID: 2115060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GH secretion in Prader-Labhard-Willi syndrome: somatotrope responsiveness to GHRH is enhanced by arginine but not by pyridostigmine.
    Beccaria L; Bosio L; Sanzari A; Aimaretti G; Ghigo E; Chiumello G
    J Pediatr Endocrinol Metab; 1996; 9(6):577-83. PubMed ID: 9004172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pyridostigmine counteracts the blunted growth hormone response to growth hormone-releasing hormone of obese children.
    Loche S; Pintor C; Cappa M; Ghigo E; Puggioni R; Locatelli V; Müller EE
    Acta Endocrinol (Copenh); 1989 May; 120(5):624-8. PubMed ID: 2499149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impairment of growth hormone responsiveness to growth hormone releasing hormone and pyridostigmine in patients affected by Prader-Labhardt-Willi syndrome.
    Beccaria L; Benzi F; Sanzari A; Bosio L; Brambilla P; Chiumello G
    J Endocrinol Invest; 1996 Nov; 19(10):687-92. PubMed ID: 9007701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of exogenous growth hormone pretreatment on the pituitary growth hormone response to growth hormone-releasing hormone alone or in combination with pyridostigmine in type I diabetic patients.
    Giustina A; Bossoni S; Bodini C; Cimino A; Pizzocolo G; Schettino M; Wehrenberg WB
    Acta Endocrinol (Copenh); 1991 Nov; 125(5):510-7. PubMed ID: 1759540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of arginine and pyridostigmine on the GHRH-induced GH rise in obesity and Cushing's syndrome.
    Procopio M; Invitti C; Maccario M; Grottoli S; Cavagnini F; Camanni F; Ghigo E
    Int J Obes Relat Metab Disord; 1995 Feb; 19(2):108-12. PubMed ID: 7735336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cholinergic receptor activation by pyridostigmine restores growth hormone (GH) responsiveness to GH-releasing hormone administration in obese subjects: evidence for hypothalamic somatostatinergic participation in the blunted GH release of obesity.
    Cordido F; Casanueva FF; Dieguez C
    J Clin Endocrinol Metab; 1989 Feb; 68(2):290-3. PubMed ID: 2493023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repeated GH-releasing hormone administration unravels different GH secretory patterns in normal adults and children.
    Ghigo E; Goffi S; Mazza E; Arvat E; Procopio M; Bellone J; Müller EE; Camanni F
    Acta Endocrinol (Copenh); 1989 May; 120(5):598-601. PubMed ID: 2499148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impairment of GH responsiveness to GH-releasing hexapeptide (GHRP-6) in Prader-Willi syndrome.
    Grugni G; Guzzaloni G; Morabito F
    J Endocrinol Invest; 2001 May; 24(5):340-8. PubMed ID: 11407654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impairment of GH responsiveness to combined GH-releasing hormone and arginine administration in adult patients with Prader-Willi syndrome.
    Grugni G; Marzullo P; Ragusa L; Sartorio A; Trifirò G; Liuzzi A; Crinò A;
    Clin Endocrinol (Oxf); 2006 Oct; 65(4):492-9. PubMed ID: 16984242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of cholinergic tone by pyridostigmine reverses the inhibitory effect of corticotropin-releasing hormone on the growth hormone-releasing hormone-induced growth hormone secretion.
    Corsello SM; Tofani A; Della Casa S; Sciuto R; Rota CA; Colasanti S; Bini A; Barini A; Barbarino A
    Acta Endocrinol (Copenh); 1992 Feb; 126(2):113-6. PubMed ID: 1543015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GH/IGF-I axis in Prader-Willi syndrome: evaluation of IGF-I levels and of the somatotroph responsiveness to various provocative stimuli. Genetic Obesity Study Group of Italian Society of Pediatric Endocrinology and Diabetology.
    Corrias A; Bellone J; Beccaria L; Bosio L; Trifirò G; Livieri C; Ragusa L; Salvatoni A; Andreo M; Ciampalini P; Tonini G; Crinò A
    J Endocrinol Invest; 2000 Feb; 23(2):84-9. PubMed ID: 10800760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GH response to GHRH combined with pyridostigmine or arginine in different conditions of low somatotrope secretion in adulthood: obesity and Cushing's syndrome in comparison with hypopituitarism.
    Procopio M; Maccario M; Savio P; Valetto MR; Aimaretti G; Grottoli S; Oleandri SE; Baffoni C; Tassone F; Arvat E; Camanni F; Ghigo E
    Panminerva Med; 1998 Mar; 40(1):13-7. PubMed ID: 9573747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GH response to GHRH combined with pyridostigmine or arginine in different conditions of low somatotrope secretion in adulthood: obesity and Cushing's syndrome in comparison with hypopituitarism.
    Procopio M; Maccario M; Savio P; Valetto MR; Aimaretti G; Grottoli S; Oleandri SE; Baffoni C; Tassone F; Arvat E; Camanni F; Ghigo E
    Minerva Endocrinol; 1999; 24(3-4):107-11. PubMed ID: 10953725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction of the pituitary GH releasable pool in short children with GH neurosecretory dysfunction.
    Aimaretti G; Bellone S; Bellone J; Chiabotto P; Baffoni C; Corneli G; Origlia C; de Sanctis C; Camanni F; Ghigo E
    Clin Endocrinol (Oxf); 2000 Mar; 52(3):287-93. PubMed ID: 10718826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low hexarelin dose and pyridostigmine have additive effect and potentiate to the same extent the GHRH-induced GH response in man.
    Arvat E; Di Vito L; Ramunni J; Gianotti L; Giordano R; Deghenghi R; Camanni F; Ghigo E
    Clin Endocrinol (Oxf); 1997 Oct; 47(4):495-500. PubMed ID: 9404449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pyridostigmine fails to increase either spontaneous or GHRH-stimulated GH secretion during day or night in growth hormone-insufficient children.
    Kirk JM; Ross RJ; Trainer PJ; Froud AL; Davies SC; Savage MO; Besser GM
    Clin Endocrinol (Oxf); 1991 May; 34(5):407-11. PubMed ID: 2060150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence against depletion of the growth hormone (GH)-releasable pool in human primary hypothyroidism: studies with GH-releasing hormone, pyridostigmine, and arginine.
    Valcavi R; Valente F; Dieguez C; Zini M; Procopio M; Portioli I; Ghigo E
    J Clin Endocrinol Metab; 1993 Sep; 77(3):616-20. PubMed ID: 8103770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.